Intestinal cancer
MONDO:0005814A malignant neoplasm involving the intestine
Also known as: bowel cancer, cancer of intestine, cancer of the intestine, intestinal cancer, intestinal neoplasms, malignant, intestinal tumors, malignant, intestine cancer, malignant intestinal neoplasm
4804 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 2133 trials in this tab.
-
Engineered immune cells take on metastatic tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control Recruiting nowThis phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to see if the treatment is safe and works against these cancers. About 360 participants will take part in this early-s…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New Antibody-Drug conjugate enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called ADCE-B05 in 180 people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to …
Phase: PHASE1 • Sponsor: Adcendo ApS • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Blood test may guide chemo choices for colon cancer patients
Disease control Recruiting nowThis study is for people with stage III colon cancer who have had surgery. It uses a blood test called Signatera to look for leftover cancer DNA. Depending on the results, patients get either immediate or delayed chemotherapy, and the type and length of chemo are tailored to thei…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug EVOLVE104 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…
Phase: PHASE1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New Antibody-Drug conjugate takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Engineered immune cells take aim at a common cancer target in Hard-to-Treat tumors
Disease control Recruiting nowThis early study tests a new treatment called SUV2208A, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack cancer cells carrying a protein called CLDN18.2. The trial enrolls up to 18 adults with advanced solid tumors that ha…
Phase: EARLY_PHASE1 • Sponsor: Celest Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Could a simple stitch prevent a common complication after pancreatic surgery?
Disease control Recruiting nowThis trial investigates whether adding a Braun anastomosis—a connection between two loops of the small intestine—during pancreatic cancer surgery can lower the risk of delayed gastric emptying, a frequent complication where the stomach takes too long to empty. About 264 adults sc…
Phase: NA • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug DM002 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…
Phase: PHASE1, PHASE2 • Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug targets cancer spread in first human trial
Disease control Recruiting nowThis early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called BMS-986488, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 437 adults w…
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug AWT020 takes on advanced solid tumors
Disease control Recruiting nowThis phase 1 trial tests a new drug called AWT020, given alone or with other cancer treatments, in people with advanced solid tumors such as non-small cell lung cancer, colorectal cancer, kidney cancer, and melanoma. The main goals are to check the drug's safety, find the best do…
Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New hope for advanced colorectal cancer: first human trial launches
Disease control Recruiting nowThis study tests a new drug called M9140 in people with advanced colorectal cancer that has not responded to standard treatments. The drug works by targeting a protein on cancer cells to deliver a chemotherapy-like agent directly to the tumor. The trial has two parts: first findi…
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug combo targets Hard-to-Treat kidney cancer
Disease control Recruiting nowThis early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Could a poop pill help heal after colon surgery?
Disease control Recruiting nowThis early study is testing whether giving a transplant of healthy gut bacteria (called IMT) through a feeding tube is safe and doable in 40 adults who have had part of their colon removed due to diverticulitis or sigmoid colon cancer. Participants get the transplant a couple of …
Phase: PHASE1 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug infusion targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New experimental drug BMS-986500 enters first human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Tailor-Made vaccine aims to train immune system against cancer
Disease control Recruiting nowThis early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…
Phase: EARLY_PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Can a pill turn on genes that stop cancer? new trial begins
Disease control Recruiting nowThis early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New targeted combo aims to outsmart Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis Phase 3 study tests whether adding the targeted drug sotorasib and another drug called panitumumab to standard chemotherapy (FOLFIRI) works better than standard chemo alone (with or without bevacizumab) for people with metastatic colorectal cancer that has a specific KRAS G1…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Cancer patients get continued access to promising drugs in new safety trial
Disease control Recruiting nowThis study offers long-term treatment with nivolumab and other cancer therapies to 1,500 patients who previously benefited from Bristol-Myers Squibb trials. The main goal is to monitor safety and side effects over time. Participants must have had a good response in their earlier …
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Texts vs. manuals: new trial aims to help rural cancer survivors kick the habit
Disease control Recruiting nowThis study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New triple therapy aims to shrink abdominal tumors in colorectal cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adding PET-guided radiation and an immunotherapy drug called cadonilimab to standard chemotherapy can shrink tumors better than chemotherapy alone in people with colorectal cancer that has spread to the lining of the abdomen. The study will e…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New trial zaps spreading colon cancer with precision: could it be a Game-Changer?
Disease control Recruiting nowThis phase III trial is testing whether adding focused treatments—like high-dose radiation, surgery, or heat ablation—to standard chemotherapy can help people with colorectal cancer that has spread to up to four sites. The goal is to see if destroying those metastatic tumors impr…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Poop pills could protect gut after colon surgery – early trial begins
Disease control Recruiting nowThis early-stage trial is testing whether a pill made from freeze-dried healthy donor stool (MTP-101P) is safe and can restore good bacteria in people having part of their colon removed. Forty adults aged 18-75 with colon polyps, early-stage cancer, or diverticulitis will take th…
Phase: PHASE1 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Zapping spreading tumors could extend life on current cancer drugs
Disease control Recruiting nowThis study tests whether adding a targeted, tumor-destroying treatment (like focused radiation or heat ablation) can help people with certain gastrointestinal cancers—such as colorectal, small bowel, or pancreatic cancer—continue their current systemic therapy longer when only a …
Phase: NA • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New pill combo takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug IMA402 targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.
Phase: PHASE1, PHASE2 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cocktail aims to outsmart Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis study is testing whether adding two new drugs (BNT314 and BNT327) to standard chemotherapy can help people with metastatic colorectal cancer that hasn't responded well to initial treatment. The trial will enroll about 482 participants across multiple sites. The goal is to se…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for Hard-to-Treat colorectal cancer? denikitug trial launches
Disease control Recruiting nowThis phase 2 trial tests a new drug called denikitug, alone or combined with other treatments, in 170 people with advanced microsatellite stable (MSS) colorectal cancer. MSS colorectal cancer is a common type that often does not respond to standard immunotherapy. The study aims t…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New immune cell therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug IPN01203 enters human trials
Disease control Recruiting nowThis study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…
Phase: PHASE1, PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat GI cancers
Disease control Recruiting nowThis study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink.…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New targeted pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…
Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy aims to boost rectal cancer survival
Disease control Recruiting nowThis phase 2 trial is testing a two-month course of chemotherapy (mFOLFOX) followed by short-course radiation before surgery for people with resectable rectal cancer. The goal is to see if this approach improves the chance of being cancer-free three years later. About 54 particip…
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New cocktail approach aims to wipe out High-Risk rectal cancer without surgery
Disease control Recruiting nowThis phase 2 trial tests a powerful mix of short-course radiation, chemotherapy (mFOLFOX6), an immunotherapy (PD-1 antibody), and a targeted drug (cetuximab or bevacizumab, depending on genetic markers) in people with high-risk rectal cancer that is mismatch repair proficient (pM…
Phase: PHASE2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Triple threat: new combo therapy targets rare rectal cancer
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (PD-1 antibody) to standard chemoradiation can improve outcomes for people with a rare type of rectal cancer called squamous cell carcinoma. About 20 adults with newly diagnosed, non-spread cancer will receive the combination.…
Phase: PHASE2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat cancers with BRAF mutation
Disease control Recruiting nowThis early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill aims to speed liver healing after cancer surgery
Disease control Recruiting nowThis study tests an experimental drug called HRX215 in people who had part of their liver removed because colon cancer spread there. The drug is meant to help the liver grow back and work better after surgery. About 80 adults will take either HRX215 or a placebo for 28 days, and …
Phase: PHASE1, PHASE2 • Sponsor: HepaRegeniX GmbH • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug IPN01195 enters human trials
Disease control Recruiting nowThis study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …
Phase: PHASE1, PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy aims to boost survival in tough rectal cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding immunotherapy and a targeted drug to short-course radiotherapy and chemotherapy improves outcomes for people with high-risk rectal cancer. About 204 participants will receive either the standard treatment or the intensified combo. The study…
Phase: PHASE3 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo immunotherapy aims to shrink colon tumors before surgery
Disease control Recruiting nowThis study tests whether giving two immunotherapy drugs (botensilimab and balstilimab) before surgery can shrink tumors and improve outcomes for people with advanced colon cancer that can be removed. About 100 adults with stage IIB to IIIC colorectal cancer will receive the drugs…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy aims to shrink rectal tumors before surgery
Disease control Recruiting nowThis phase 2 trial will test whether adding immunotherapy drugs (cemiplimab alone or with fianlimab or REGN7075) to standard chemotherapy (capecitabine and oxaliplatin) can completely eliminate tumors in patients with locally advanced rectal cancer before surgery. The study plans…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could old drugs beat rare cancers? new trial aims to find out
Disease control Recruiting nowThe DETERMINE trial is testing whether drugs already approved for some cancers can help people with rare cancers or common cancers that have rare genetic mutations. It will enroll 825 adults, teenagers, and children whose cancers have specific DNA changes. The goal is to find new…
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a tailored quit-smoking program help cancer patients and survivors kick the habit for good?
Disease control Recruiting nowThis study explores how to best help cancer patients, survivors, and their caregivers quit tobacco. Participants can choose between group or one-on-one counseling sessions. The goal is to see if this program is practical and well-received, paving the way for better tobacco cessat…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for advanced cancers? early trial of PYX-201 begins
Disease control Recruiting nowThis early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…
Phase: PHASE1 • Sponsor: Pyxis Oncology, Inc • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill for Hard-to-Treat cancers enters first human tests
Disease control Recruiting nowThis early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…
Phase: PHASE1 • Sponsor: Degron Therapeutics Co. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Simple stent may cut pancreatic leak risk after major surgery
Disease control Recruiting nowThis study tests whether placing a small tube (stent) in the pancreas during Whipple surgery can prevent a common complication called pancreatic fistula, where digestive fluid leaks out. The trial will compare 100 patients with a soft pancreas who either get the stent or not. The…
Phase: NA • Sponsor: Minia University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo trial aims to fight advanced cancers
Disease control Recruiting nowThis study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug duo aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called nenocorilant combined with the immunotherapy nivolumab in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 50 participants w…
Phase: PHASE1, PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for hard-to-treat colon cancer? phase 3 trial launches
Disease control Recruiting nowThis study tests whether adding the experimental drug INCA33890 to standard chemotherapy and bevacizumab helps people with metastatic colorectal cancer that is microsatellite stable (a type that doesn't respond well to immunotherapy). About 700 adults who have not had prior treat…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat colorectal tumors
Disease control Recruiting nowThis study tests an experimental drug called telisotuzumab adizutecan combined with standard chemotherapy in people whose colorectal cancer has spread. The goal is to see if the combination shrinks tumors and is safe. About 390 adults will take part at hospitals worldwide.
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo aims to shrink hard-to-treat gut tumors
Disease control Recruiting nowThis study tests a new drug called DR30206 combined with standard treatments for people with advanced or spreading gastrointestinal cancers, like colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. About 186 adults in China will take part.
Phase: PHASE1, PHASE2 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for Tough-to-Treat colorectal cancer: phase 3 trial launches
Disease control Recruiting nowThis Phase 3 study tests a new drug, telisotuzumab adizutecan, combined with bevacizumab, against the standard treatment (LONSURF plus bevacizumab) in 700 adults with advanced colorectal cancer that has stopped responding to prior therapies. The goal is to see if the new combo sh…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental drug E303 enters human trials
Disease control Recruiting nowThis early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …
Phase: PHASE1 • Sponsor: Samsung Bioepis Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Radiation and immunotherapy join forces against Hard-to-Treat liver metastases
Disease control Recruiting nowThis study tests whether combining a precise form of radiation (SBRT) with an immunotherapy drug (PD-1 monoclonal antibody) can help people whose colorectal cancer has spread to the liver and cannot be removed surgically. The trial enrolls adults aged 18 to 75 with a specific typ…
Phase: PHASE3 • Sponsor: Jun Huang • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Old antibiotic, new hope: novobiocin targets Cancer's weak DNA repair
Disease control Recruiting nowThis early-phase trial tests an antibiotic called novobiocin in people with advanced solid tumors that have specific DNA repair mutations (like BRCA). The drug blocks a protein cancer cells use to fix their damaged DNA, which may cause them to die. The study aims to find the safe…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for advanced cancer: LBL-024 trial now recruiting
Disease control Recruiting nowThis study is testing an experimental drug called LBL-024 in people with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 396 adults aged 18 to 80 are taking part. The drug is given…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New radiation boost strategy aims to spare rectal cancer patients from surgery
Disease control Recruiting nowThis study tests two ways of giving extra radiation after standard chemoradiation to people with early-stage rectal cancer. The goal is to see which method helps more people achieve a complete response, so they can avoid major surgery and keep their rectum. About 131 participants…
Phase: PHASE2, PHASE3 • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Cancer drug adagrasib offers continued hope in rollover trial
Disease control Recruiting nowThis study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…
Phase: PHASE2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Experimental vaccine targets Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis early-phase trial is testing a new vaccine made from genetically modified tumor cells in 9 adults with advanced pMMR colorectal cancer who have run out of standard options. The vaccine is given as a series of injections to see if it is safe and can stimulate the immune syste…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo aims to spare rectal cancer patients from surgery
Disease control Recruiting nowThis phase II trial tests whether giving a combination of chemotherapy (FOLFOX) and two immunotherapy drugs (botensilimab and balstilimab) before surgery can eliminate rectal cancer without the need for surgery or radiation. The study includes adults with stage II or III rectal c…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental combo aims to tackle stubborn colorectal cancer
Disease control Recruiting nowThis trial is testing whether combining pidnarulex (a drug that blocks cancer cell growth) with cemiplimab (an immunotherapy that helps the immune system attack cancer) is safe and effective for people with advanced colorectal cancer that no longer responds to standard treatments…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a vitamin b derivative boost chemo for advanced colon cancer?
Disease control Recruiting nowThis study tests a new drug called arfolitixorin for people with metastatic colorectal cancer (cancer that has spread). The drug is a form of vitamin B that may make standard chemotherapy work better. About 90 participants will receive arfolitixorin along with usual chemo drugs, …
Phase: PHASE1, PHASE2 • Sponsor: Isofol Medical AB • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug XMT-1660 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo takes on tough tumors
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will…
Phase: PHASE1 • Sponsor: CytomX Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New immune drug STK-012 takes on tough lung cancers
Disease control Recruiting nowThis study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …
Phase: PHASE1, PHASE2 • Sponsor: Synthekine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat solid tumors
Disease control Recruiting nowThis study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New immunotherapy combo aims to extend life in Tough-to-Treat colorectal cancer
Disease control Recruiting nowThis Phase 3 trial is testing whether a combination of two immunotherapy drugs, botensilimab and balstilimab, can help people with advanced colorectal cancer that can't be removed by surgery and has stopped responding to chemotherapy. About 834 participants will receive either th…
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug MK-4884 tested for safety in advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental cancer combo enters early human testing
Disease control Recruiting nowThis early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the com…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Sparing lymph nodes during radiation may boost immune attack on rectal cancer
Disease control Recruiting nowThis phase 2 trial compares two treatment plans for people with locally advanced rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). One group receives standard short-course radiation followed by chemotherapy. The other group receives a newer a…
Phase: PHASE2 • Sponsor: Dechang Diao • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug shows promise for Hard-to-Treat GI cancers
Disease control Recruiting nowThis study is testing a drug called patritumab deruxtecan in people with advanced gastrointestinal cancers that have spread. The drug is given through a vein and aims to shrink tumors. The trial will check how safe the drug is and how many people's cancers respond to treatment. A…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat RAS-Mutant cancers
Disease control Recruiting nowThis study tests whether combining experimental RAS(ON) inhibitors with ivonescimab (an immunotherapy) can shrink or control advanced solid tumors that have a RAS mutation. About 370 adults with cancers like non-small cell lung cancer or colorectal cancer will receive these drugs…
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New cancer drug YL211 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…
Phase: PHASE1 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill targets Hard-to-Treat KRAS cancers in first human trial
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…
Phase: PHASE1 • Sponsor: Kestrel Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug CR-001 enters human trials
Disease control Recruiting nowThis study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: Crescent Biopharma, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a Stress-Boosting drug make immunotherapy work for Hard-to-Treat colorectal cancer?
Disease control Recruiting nowThis phase 1 trial tests a new two-drug combination for people with metastatic colorectal cancer that is microsatellite stable (MSS), a type that typically does not respond to immunotherapy alone. The study combines LB-100, which blocks a protein called PP2A to increase stress si…
Phase: PHASE1 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: enhertu studied in 20+ tumor types
Disease control Recruiting nowThis study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Triple drug cocktail targets Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis study tests whether a combination of three drugs—adagrasib, cetuximab, and cemiplimab—can help control metastatic colorectal cancer in people whose tumors have a specific genetic change called KRAS G12C. About 31 adults whose cancer has not responded to at least one prior tr…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: first human trial of ERAS-0015 begins
Disease control Recruiting nowThis early-stage trial tests a new oral drug called ERAS-0015, alone or with other cancer drugs, in 600 adults with advanced solid tumors that have certain RAS mutations. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researc…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cocktail of drugs aims to tackle tough colorectal cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adding two immune-boosting drugs (ongericimab and toripalimab) to standard second-line chemotherapy can shrink tumors in people with advanced MSS/pMMR colorectal cancer. The study enrolls 32 adults whose cancer progressed after first-line tre…
Phase: PHASE2 • Sponsor: Shanghai Pudong Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Keytruda's Long-Term safety under the microscope in massive cancer trial
Disease control Recruiting nowThis study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cocktail of old drugs takes on advanced cancers
Disease control Recruiting nowThis Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…
Phase: PHASE2 • Sponsor: Sarcoma Oncology Research Center, LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Blood test could guide anal cancer treatment, reducing side effects
Disease control Recruiting nowThis study tests whether a blood test (ctDNA) can help doctors customize the dose of chemoradiation for people with anal cancer. Depending on how the tumor responds, some patients may get a lower radiation dose to reduce side effects, while others may get a higher dose or an adde…
Phase: PHASE2 • Sponsor: Jennifer Dorth • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cancer pill SNV1521 enters human testing
Disease control Recruiting nowThis early-stage trial tests a new oral drug called SNV1521 in 400 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Researchers will also test SNV1521 combined with other cancer drugs.
Phase: PHASE1 • Sponsor: Synnovation Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for stomach and bowel cancers: experimental drug Rina-S enters Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial is testing a new drug called Rina-S (rinatabart sesutecan) in about 160 people with advanced gastrointestinal cancers that have spread or cannot be removed. The drug is given alone through an IV, and everyone receives it—no placebo. The study will check if the …
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New cancer drug TQB3142 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called TQB3142 in 66 adults with advanced tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and look f…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could skipping chemo be safer for early rectal cancer?
Disease control Recruiting nowThis trial tests whether close follow-up (active surveillance) is as good as chemoradiotherapy for preventing cancer return after early-stage rectal cancer removal. About 480 adults with intermediate-risk T1 rectal cancer will be randomly assigned to either regular checkups and s…
Phase: NA • Sponsor: Medical University of Gdansk • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug XTX301 takes on advanced cancers in first human trial
Disease control Recruiting nowThis study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New device aims to prevent leaks after colon cancer surgery
Disease control Recruiting nowThis study tests a device called ColoSeal ICD that is placed inside the colon after surgery to divert stool away from the surgical connection. The goal is to see if it is safe and feasible in 90 adults with rectal or rectosigmoid cancer. The device stays in place for about 10 day…
Phase: NA • Sponsor: Averto Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New combo aims to reboot immunotherapy in resistant cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…
Phase: PHASE1, PHASE2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New immune drug PHST001 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…
Phase: PHASE1 • Sponsor: Pheast Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New cancer antibody ONC-841 enters human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called ONC-841 in people with advanced solid tumors that have spread. The drug is an antibody designed to help the immune system attack cancer cells. The study will first find a safe dose, then test it alone and with standard treatments for…
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for Hard-to-Treat cancers? early trial launches
Disease control Recruiting nowThis first-in-human study tests an experimental drug called CX-2051, alone or with Avastin, in 160 adults with advanced solid tumors that have worsened after standard treatment. The main goals are to check safety and find the right dose, while also looking for early signs of tumo…
Phase: PHASE1 • Sponsor: CytomX Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New pill targets Hard-to-Treat cancers with rare TP53 mutation
Disease control Recruiting nowThis study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …
Phase: PHASE1, PHASE2 • Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New cancer drug BI 3810944 enters first human tests
Disease control Recruiting nowThis early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New surgery aims to shield fertility in women undergoing pelvic radiation
Disease control Recruiting nowThis phase I trial tests a surgical procedure called utero-ovarian transposition (UOT) to temporarily move the uterus, ovaries, and fallopian tubes out of the radiation field in women aged 18-40 with pelvic cancers. The goal is to preserve fertility and ovarian function during wh…
Phase: NA • Sponsor: University of South Florida • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New cancer drug BBO-10203 enters first human trials
Disease control Recruiting nowThis early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Belzutifan extension trial aims to extend lives in VHL and advanced cancer
Disease control Recruiting nowThis extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Warm during surgery? new trial tests if temperature control boosts survival in older cancer patients
Disease control Recruiting nowThis study tests whether carefully managing body temperature during major cancer surgery can lower the risk of postoperative delirium (sudden confusion) and improve long-term survival in patients aged 65 and older. About 4,000 participants will be randomly assigned to either rout…
Phase: NA • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to shrink rectal tumors faster
Disease control Recruiting nowThis study compares a new treatment approach for high-risk rectal cancer: short-course radiation followed by immunotherapy (toripalimab) and chemotherapy (FOLFOX) versus the standard long-course chemoradiation. The goal is to see if the new approach leads to more complete tumor r…
Phase: PHASE2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Cancer patients on targeted therapy get extended safety monitoring
Disease control Recruiting nowThis study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for Hard-to-Treat cancers? early trial launches
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug called XB628, alone or with an oral drug called zanzalintinib, in people with advanced or metastatic solid tumors that have not responded to prior treatments. The study has two parts: first, finding a safe dose, and then check…
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New study matches colorectal cancer patients to precision drugs
Disease control Recruiting nowThis study tests the safety and effectiveness of targeted therapies or immunotherapies in people with metastatic colorectal cancer (cancer that has spread). Participants are assigned to a treatment based on specific biomarkers found in their tumor. The goal is to see if these per…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to wipe out rectal cancer before surgery
Disease control Recruiting nowThis phase 2 trial tests a new approach for people with locally advanced rectal cancer. Participants first receive a short course of radiation, followed by a combination of immunotherapy (sintilimab and IL-2) and chemotherapy (CAPOX). The goal is to see if this treatment can make…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat solid tumors
Disease control Recruiting nowThis trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Pancreas cancer surgery showdown: total removal may boost survival
Disease control Recruiting nowThis study looks at whether removing the entire pancreas is better than removing just part of it for people with certain cancers in the head of the pancreas who are at high risk of complications. The main goal is to see if total removal helps patients live longer without hurting …
Phase: NA • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for Hard-to-Treat cancers: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill combo aims to shrink Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…
Phase: PHASE1, PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
MRNA vaccine technology takes on advanced cancers
Disease control Recruiting nowThis study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…
Phase: PHASE1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New Dual-Antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…
Phase: PHASE1, PHASE2 • Sponsor: Ottimo Pharma Limited • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug JNJ-89402638 enters human trials for Tough-to-Treat GI cancers
Disease control Recruiting nowThis early-phase study is testing an experimental drug called JNJ-89402638 in people with metastatic colorectal or gastric cancer that has progressed after at least two prior treatments. The trial will first find the safest dose and schedule, then test the drug alone or combined …
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could some rectal cancer patients skip surgery? new study investigates
Disease control Recruiting nowThis study is testing whether active surveillance (watchful waiting) is as safe as surgery for people with low rectal cancer who have a complete response after chemoradiotherapy. About 90 participants will be monitored for 2 years to see how often the cancer returns and whether d…
Phase: NA • Sponsor: Mount Sinai Hospital, Canada • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug could protect children with cancer from chemo side effects
Disease control Recruiting nowThis study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.
Phase: PHASE2 • Sponsor: Spectrum Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for advanced bowel cancer: experimental drug combo enters major trial
Disease control Recruiting nowThis study tests whether a new drug called pumitamig, combined with chemotherapy, works better than the current standard treatment (bevacizumab plus chemo) for people with advanced colorectal cancer that cannot be removed by surgery. About 990 adults who have not yet been treated…
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for advanced colon cancer: experimental drug combo enters phase 3 trial
Disease control Recruiting nowThis phase 3 study tests whether a new drug called ivonescimab, combined with standard chemotherapy (FOLFOX), works better than the current standard treatment (bevacizumab plus FOLFOX) for people with metastatic colorectal cancer that has spread. About 600 adults who have not had…
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental cancer drug enters human testing
Disease control Recruiting nowThis early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug RSC-1255 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests an experimental drug called RSC-1255, given alone or with hydroxychloroquine, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The study has two parts: first, finding a safe dose, and …
Phase: PHASE1 • Sponsor: RasCal Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Recruiting nowThis study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New chemo cocktail targets rare small bowel tumors
Disease control Recruiting nowThis phase 2 trial tests a four-drug chemotherapy combination called NALIRIFOX in 36 adults with advanced small bowel adenocarcinoma that cannot be removed by surgery. The drugs are given intravenously on days 1 and 15 of each 28-day cycle for up to 6 cycles, followed by a milder…
Phase: PHASE2 • Sponsor: Tiago Biachi de Castria • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill targets Hard-to-Treat cancers with specific gene mutation
Disease control Recruiting nowThis study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…
Phase: PHASE1, PHASE2 • Sponsor: Ensem Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug BG-C477 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Hard-to-Treat cancers: first human trial of BGB-58067 begins
Disease control Recruiting nowThis early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Smart patch lets gut surgery patients go home days earlier
Disease control Recruiting nowThis study tests a wearable patch called MultiSense that tracks heart rate and other vital signs for five days after a patient leaves the hospital following major digestive surgery. The goal is to see if the patch allows high-risk patients to be discharged earlier while still cat…
Phase: NA • Sponsor: Rhythm Diagnostic Systems • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New study offers navigation, education, and rides to boost colon cancer screening Follow-Up
Disease control Recruiting nowThis study tests whether a program that includes a patient navigator, an educational video about colonoscopy, and a free rideshare ride home can help more people complete a follow-up colonoscopy after an abnormal stool-based colorectal cancer screening test. About 682 adults aged…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New enzyme shot takes aim at Hard-to-Treat tumors
Disease control Recruiting nowThis trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…
Phase: PHASE1, PHASE2 • Sponsor: Onchilles Pharma Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Hard-to-Treat cancers: targeted drug combo enters phase 2 trial
Disease control Recruiting nowThis phase 2 trial is testing a drug called calderasib (MK-1084), given alone or with cetuximab, in 150 people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the cancer shrinks or disappears and to check for side effects. Participants mu…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Personalized cell therapy takes on GI cancers
Disease control Recruiting nowThis study tests a new treatment for gastrointestinal cancer using a patient's own immune cells, which are engineered in a lab to target cancer. About 100 participants will receive these cells to see if they are safe and can shrink tumors. The trial is currently recruiting and co…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Hard-to-Treat cancers: drug targets DNA repair weakness
Disease control Recruiting nowThis phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug targets Hard-to-Treat cancers with KRAS mutation
Disease control Recruiting nowThis early-stage study is testing a new drug called calderasib (MK-1084) in people with advanced solid tumors that have a specific KRAS G12C mutation. The drug is given alone or combined with other cancer treatments. The main goals are to check safety and find the right dose. Abo…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill targets Hard-to-Treat cancers with hippo pathway mutations
Disease control Recruiting nowThis study tests a new drug called SW-682, taken as a tablet, for people with advanced solid tumors that have not responded to standard treatments. The trial focuses on tumors with changes in the Hippo pathway, including mesothelioma. In the first part, doctors will find the safe…
Phase: PHASE1 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New immune therapy targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment made from a patient's own immune cells (TILs) for metastatic colorectal or prostate cancer. The goal is to see if repeated doses are safe and feasible in 12 participants. The therapy aims to help the immune system fight cancer, but ong…
Phase: PHASE1, PHASE2 • Sponsor: CuraCell TX AB • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Supercharged immune cells take on cancer in new trial
Disease control Recruiting nowThis study tests whether specially engineered immune cells (EIE) can safely fight cancer. Researchers take a patient's own immune cells, modify them to target tumor-related markers, and infuse them back. The trial involves 100 people with various cancers whose tumors show specifi…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New strategy: removing tumors one by one after chemo for stomach and pancreatic cancers
Disease control Recruiting nowThis phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Radioactive 'Smart Bombs' target Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests two radioactive drugs, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced solid tumors that have a protein called GRPR on their surface. These cancers include certain breast, prostate, and colorectal cancers that have stopped responding …
Phase: PHASE1 • Sponsor: Alpha-9 Oncology USA Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cancer drug ZL-6201 enters early human testing
Disease control Recruiting nowThis early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.
Phase: PHASE1 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a coordinated care program boost quality of life for cancer patients facing social hardships?
Disease control Recruiting nowThis study tests a program called Comprehensive Connected Cancer Care (C4) for people newly diagnosed with cancer who also have social needs (like trouble paying for medicine or getting to appointments). The program uses patient navigators, a digital needs assessment, and better …
Phase: NA • Sponsor: Timothy Mullett • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…
Phase: PHASE1 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug YL201 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called YL201 in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then testing that dose in more patients with specific cancer types. YL201 is given by IV every t…
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Tailored chemo doses could boost GI cancer treatment
Disease control Recruiting nowThis study tests a new way to give chemotherapy for gastrointestinal cancers like colorectal and stomach cancer. Doctors will adjust the dose of one chemo drug (5-FU) based on how well each patient tolerates it, aiming to give higher doses to those who can handle it without sever…
Phase: NA • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C137, which delivers chemotherapy directly to cancer cells that have a specific marker (FGFR2b). The goal is to see if it is safe and can shrink tumors in people with advanced solid tumors who have run out of standard options. Abo…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets tough cancers with KRAS G12D mutation
Disease control Recruiting nowThis early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Nanoparticles boost radiation against tough brain tumors
Disease control Recruiting nowThis study tests whether adding AGuIX gadolinium-based nanoparticles to standard brain radiation can better control brain metastases that are at high risk of coming back. About 134 adults with certain cancers (like melanoma, lung, breast, or colorectal) that have spread to the br…
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug AO-252 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…
Phase: PHASE1 • Sponsor: A2A Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody drug targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…
Phase: PHASE1 • Sponsor: Chiome Bioscience Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radioactive drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New trial matches cancer patients to smart drug bombs
Disease control Recruiting nowThis phase II trial is testing whether three antibody-drug conjugates (ADCs) can shrink advanced or metastatic solid tumors that have high levels of specific proteins (Trop-2, nectin-4, or HER2). About 500 patients will first have their tumors tested for these markers, then recei…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to shrink hard-to-treat cancers
Disease control Recruiting nowThis study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Liver pump chemotherapy may boost survival in advanced colorectal cancer
Disease control Recruiting nowThis phase 3 trial is testing whether adding a chemotherapy pump that delivers drugs directly to the liver (hepatic arterial infusion, or HAI) can help people with colorectal cancer that has spread to the liver and cannot be removed by surgery. About 408 participants will receive…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New surgical wrap could slash deadly leak risk in rectal cancer patients
Disease control Recruiting nowThis study tests whether using a special reinforcing material (SIS) during bowel reconnection after rectal cancer surgery can prevent dangerous leaks. About 966 adults with mid-to-low rectal cancer will be randomly assigned to receive either the reinforced connection or the stand…
Phase: PHASE4 • Sponsor: Beijing Chao Yang Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced cancer: experimental drug targets Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…
Phase: EARLY_PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer drug H1710 enters first human tests
Disease control Recruiting nowThis early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …
Phase: PHASE1 • Sponsor: Shenzhen Hepalink Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail takes on seven tough cancers
Disease control Recruiting nowThis phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests the safety and best dose of two drugs, ZEN003694 and abemaciclib, given together. It is for people with advanced breast cancer, NUT carcinoma, or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the combinatio…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for cancer patients with autoimmune conditions: immune checkpoint inhibitor trial expands access
Disease control Recruiting nowThis study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer-Fighting viruses take on advanced tumors in early trial
Disease control Recruiting nowThis phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets tough cancers with genetic flaw
Disease control Recruiting nowThis study tests an experimental oral drug, GSK5460025, alone or with other cancer drugs, in adults whose solid tumors have specific genetic changes (dMMR or MSI-H). The goal is to see if the drug can shrink tumors and to check its safety. About 47 people with advanced cancers th…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can steroids help cancer patients resume a promising therapy?
Disease control Recruiting nowThis study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug IDE034 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests whether a combination of two drugs (ZEN003694 and talazoparib) can shrink tumors in people with advanced solid cancers that have stopped responding to standard treatments. About 88 adults will take part. Researchers will also look at participants' genes to see if…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing two experimental drugs, peposertib and tuvusertib, together in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and to understand side effects. About 66 participants wi…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to tackle Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis Phase 2 trial is testing two experimental drugs (SSGJ-705 and SSGJ-612) with or without chemotherapy in 150 adults with advanced HER2-positive solid tumors, including colorectal, bladder, breast, bile duct, and stomach cancers. The goal is to see if the combination can shrin…
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a lighter radiation punch still knock out rectal cancer?
Disease control Recruiting nowThis study tests whether a lower dose of short-course radiotherapy, combined with chemotherapy and two immune-boosting drugs, works as well as the standard radiation dose for locally advanced rectal cancer. About 122 adults will be randomly assigned to one of two radiation doses,…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Robot vs. transanal surgery: which is better for low rectal cancer?
Disease control Recruiting nowThis study compares two modern surgical techniques for removing low rectal cancer: transanal total mesorectal excision (taTME) and robot-assisted total mesorectal excision (RTME). Researchers want to see which method leads to fewer complications and less need to switch to open su…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug IDE574 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called IDE574 in people with advanced solid tumors or a specific type of breast cancer (ER+, HER2-). The drug targets two enzymes that help cancer cells grow. The study has two parts: first, testing IDE574 alone in various cancers; second, combining it…
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: targeted drug enters human trials
Disease control Recruiting nowThis early-stage trial tests a new drug, BAY 3771249, that targets a specific cancer-driving mutation called KRAS G12D. It is for people with advanced or metastatic colorectal cancer who have this mutation and have tried other treatments. The drug is given alone or with another c…
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail aims to shrink tough colorectal tumors
Disease control Recruiting nowThis Phase 2 trial tests whether adding an experimental drug (ONO-4578) and an immunotherapy (Opdivo) to standard chemotherapy and bevacizumab can shrink tumors better than standard care alone in people with advanced colorectal cancer that is not MSI-high and has PD-L1 expression…
Phase: PHASE2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Smart drain could spot deadly leaks after bowel surgery
Disease control Recruiting nowThis trial tests a new device called xBar that adds sensors to a standard surgical drain. The goal is to continuously monitor the surgical connection (anastomosis) after colorectal cancer surgery and spot leaks early. The study will enroll 80 adults and compare their recovery to …
Phase: NA • Sponsor: Exero Medical Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced cancer? first human trial of BNT3212 begins
Disease control Recruiting nowThis early-phase trial is testing a new experimental drug called BNT3212, alone or with another drug (pumitamig), in 375 adults with advanced solid tumors who have no other treatment options. The main goals are to check safety, find the right dose, and get an early look at whethe…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New radiation treatment shows promise for cancer patients
Disease control Recruiting nowThis study is testing a new type of radiation therapy called DaRT for people with malignant tumors. The main goal is to see how safe the treatment is and what side effects occur. Researchers will also check if the tumors shrink three months after treatment. About 100 adults with …
Phase: NA • Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted combo aims to outsmart Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis phase 3 trial is testing whether adding the targeted drugs calderasib and cetuximab to standard chemotherapy can help people with a specific gene mutation (KRAS G12C) in advanced colorectal cancer live longer without their cancer growing. About 477 participants will receive …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug OVV-01 injected into tumors shows promise in early trial
Disease control Recruiting nowThis early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…
Phase: PHASE1 • Sponsor: Joint Biosciences Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could zapping thigh muscles and sipping protein shakes stop muscle wasting after cancer surgery?
Disease control Recruiting nowThis trial investigates whether using a device that sends mild electrical pulses to the thigh muscles (neuromuscular electrical stimulation, or NMES) can prevent muscle loss and weakness after abdominal surgery for colorectal or gastric cancer. Some participants will also receive…
Phase: NA • Sponsor: University of Nottingham • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Antibody-Drug conjugate IM-1617 enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New biologic drug GEN1106 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New PARP1 inhibitor IMP1734 enters human trials for advanced cancers
Disease control Recruiting nowThis study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…
Phase: PHASE1, PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Tough-to-Treat colon cancer: experimental drug combo enters final testing
Disease control Recruiting nowThis Phase 3 trial tests a new drug called precemtabart tocentecan, alone or with bevacizumab, against a standard treatment for metastatic colorectal cancer that has progressed after prior therapies. About 1,020 participants will be randomly assigned to one of three treatment gro…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New biologic drug CM518D1 enters human trials for advanced cancers
Disease control Recruiting nowThis study tests a new biologic drug, CM518D1, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors. About 434 par…
Phase: PHASE1, PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug STP938 tested in patients with incurable cancers
Disease control Recruiting nowThis early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special g…
Phase: PHASE1 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Smart dosing: tailoring cancer drug levels could extend life for colorectal patients
Disease control Recruiting nowThis Phase 3 trial tests whether adjusting the dose of bevacizumab based on each patient's drug levels can better control metastatic colorectal cancer. About 244 people will receive either standard or personalized dosing alongside chemotherapy. The main goal is to see if personal…
Phase: PHASE3 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug BAL0891 enters human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…
Phase: PHASE1 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy duo takes on tough rectal cancer
Disease control Recruiting nowThis study tests whether two immunotherapy drugs, botensilimab and balstilimab, can shrink or eliminate rectal tumors in people with a specific type of rectal cancer (MMRp/MSS) that usually doesn't respond to immunotherapy alone. About 40 adults with stage II or III rectal cancer…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to stall advanced cancers
Disease control Recruiting nowThis early-phase trial tests a combination of two drugs—temozolomide and M1774—in people with advanced solid tumors that have spread. Temozolomide damages cancer cell DNA, while M1774 blocks enzymes that help cancer grow. The goal is to find the best dose and see if the combo can…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Zapping resistant tumors may extend life of cancer drugs
Disease control Recruiting nowThis study tests whether adding a precise local treatment—like focused radiation or ablation—can help people whose cancer has a few new or growing spots while on standard therapy. Participants continue their usual medication while the resistant tumors are treated directly. The go…
Phase: NA • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Supercharged immune cells take on hard-to-treat pancreatic cancer
Disease control Recruiting nowThis early-phase study tests a new combination treatment for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered immune cells (NK cells) from donated cord blood, given through a belly infusion and a vein,…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for advanced colon cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs (fruquintinib and FOLFIRI) in people with advanced colorectal cancer that has spread. It is for those who have already had one prior treatment. The goal is to see if this new combination can help control the cancer longer and with manag…
Phase: PHASE2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New cancer drug MBS8(1V270) enters first human trials
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…
Phase: PHASE1 • Sponsor: MonTa Biosciences ApS • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
MRI-Guided radiation tailors treatment for anal cancer patients
Disease control Recruiting nowThis phase 2 trial tests a new way to deliver radiation therapy for anal cancer using MRI guidance to adjust doses based on each patient's risk level. About 80 adults with anal squamous cell carcinoma will receive different radiation schedules depending on their tumor risk group.…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Cancer drug pelabresib gets Long-Term safety check in extension trial
Disease control Recruiting nowThis study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo therapy aims to shrink advanced tumors
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Blood test could steer cancer treatment to right drug
Disease control Recruiting nowThis phase II trial tests whether a blood test that looks for genetic changes in circulating tumor cells can help doctors choose the right targeted therapy for colorectal cancer. 150 participants will either get treatment guided by the blood test or standard care. The goal is to …
Phase: PHASE2 • Sponsor: Matteo's Friends • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental immune therapy aims to tackle HPV cancers before standard care
Disease control Recruiting nowThis study tests whether a single infusion of a patient's own genetically engineered immune cells (E7 TCR-T cells) can shrink or eliminate HPV-related cancers before the patient receives standard treatment like chemo-radiation or surgery. The trial enrolls 15 adults with advanced…
Phase: PHASE1, PHASE2 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo aims to outsmart Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…
Phase: PHASE1 • Sponsor: Epkin • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing whether a new drug called ZEN003694, when added to the chemotherapy capecitabine, is safe for people with advanced solid tumors that have spread or can't be removed by surgery. About 30 participants will receive the combination to find the best d…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a cancer drug spare some patients from colon surgery?
Disease control Recruiting nowThis study tests a drug called dostarlimab in 25 people with stage II or III colon cancer that has a specific genetic feature (dMMR). The drug is given before any surgery to see if it can shrink the tumor enough that surgery may not be needed. Participants receive the drug every …
Phase: PHASE2 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New cancer cocktail enters human testing
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called CHS-114 combined with the immunotherapy toripalimab, with or without standard chemotherapy, in 154 people with advanced or metastatic solid tumors. The main goal is to see if the combination is safe and to get an early…
Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo pill aims to extend life in tough bile duct cancer
Disease control Recruiting nowThis study tests whether adding an experimental drug (D07001) to standard chemotherapy (capecitabine) helps people with advanced bile duct cancer live longer. About 195 adults whose cancer has not responded to earlier treatments will receive either D07001 or a placebo, plus capec…
Phase: PHASE3 • Sponsor: InnoPharmax Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Lab-Grown immune cells take on dangerous viruses in vulnerable patients
Disease control Recruiting nowThis study tests whether specially grown donor immune cells (called cytotoxic T lymphocytes) can safely and effectively control BK and JC virus infections in people with weakened immune systems, such as those with cancer, HIV, or organ transplants. About 100 participants will rec…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo shows promise for tough cancers
Disease control Recruiting nowThis study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 par…
Phase: PHASE1, PHASE2 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New shot could make cancer treatment easier for patients with advanced tumors
Disease control Recruiting nowThis study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug AN8025 tested in patients with advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…
Phase: PHASE1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug MG2512 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called MG2512 in about 116 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also w…
Phase: PHASE1 • Sponsor: Shanghai Mabgen Biopharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for liver metastases: immune booster combined with targeted chemo
Disease control Recruiting nowThis study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can help people with colorectal, bile duct, or adrenal cancer that has spread to the liver. About 70 adults will receive the drug combination along with a s…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New t cell engager takes on tough colorectal cancer
Disease control Recruiting nowThis early-phase trial tests a new drug called CBI-1214 in 80 people with advanced colorectal cancer that has not responded to standard treatments. CBI-1214 is designed to connect the body's own immune T cells to cancer cells, helping the immune system attack the tumor. The main …
Phase: PHASE1 • Sponsor: Cartography Biosciences • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New radiation method targets tough tumors
Disease control Recruiting nowThis phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…
Phase: PHASE2 • Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug CT-95 targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…
Phase: PHASE1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Roche offers lifeline: continued cancer drug access for trial patients
Disease control Recruiting nowThis study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Smart immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…
Phase: PHASE1, PHASE2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Supercharged immune cells take on HPV cancers
Disease control Recruiting nowThis study tests a new immunotherapy for people with advanced HPV-related cancers, such as cervical, throat, anal, and penile cancers. Participants receive specially engineered immune cells designed to attack cancer cells carrying the HPV16 virus. The goal is to see if this treat…
Phase: PHASE2 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for Hard-to-Treat colorectal cancer? drug combo trial launches
Disease control Recruiting nowThis phase 2 trial is testing whether combining the drug pirfenidone with an immunotherapy (PD-1 inhibitor), and possibly adding focused radiation, can help people with advanced colorectal cancer that hasn't responded to standard treatments. The study will enroll 48 adults aged 1…
Phase: PHASE2 • Sponsor: Tao Zhang • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug THE-0504 enters human testing for tough cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called THE-0504 in 30 adults with advanced solid tumors, including lung, colon, stomach, breast, and pancreatic cancers. The main goal is to see if the drug is safe and to find the best dose. Researchers will also watch for any signs t…
Phase: PHASE1 • Sponsor: Thena Biotech S.r.l. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Virus therapy joins Chemo-Radiation in fight against rectal cancer
Disease control Recruiting nowThis early-phase trial tests a new treatment called NG-350A, a virus designed to stimulate the immune system inside tumors, combined with standard chemoradiotherapy for people with locally advanced rectal cancer. The study aims to see if this combination can improve the chance of…
Phase: PHASE1 • Sponsor: Akamis Bio • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can immunotherapy stop colorectal Cancer's return?
Disease control Recruiting nowThis study tests if immunotherapy drugs (cemiplimab, fianlimab, and REGN7075) can clear leftover cancer DNA in the blood of colorectal cancer patients after surgery and chemotherapy. The goal is to delay or prevent the cancer from coming back. About 79 adults with stage II/III co…
Phase: PHASE2 • Sponsor: NSABP Foundation Inc • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Targeted pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis phase 2 trial tests the drug avapritinib in 50 adults with advanced solid tumors that have mutations in the CKIT or PDGFRA genes. The drug blocks enzymes that help cancer cells grow. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail targets tough colorectal cancers
Disease control Recruiting nowThis phase 2 trial tests whether a combination of three drugs—avutometinib, defactinib, and cetuximab—can help control advanced colorectal cancer that has stopped responding to standard anti-EGFR treatment. About 33 participants will receive the drugs orally and intravenously. Th…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New radioactive drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug that delivers radiation directly to cancer cells carrying a specific protein called GRPR. The study includes 48 adults with advanced cancers like prostate, breast, lung, or colon cancer that have not responded to standard treatments. The ma…
Phase: PHASE1 • Sponsor: Orano Med Theranostics, SAS • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill targets KRAS cancers in early human trial
Disease control Recruiting nowThis early-phase trial tests an oral drug called ALTA3263 in about 448 adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a KRAS mutation. The main goals are to check safety, find the right dose, and see how the body processes the drug. Part…
Phase: PHASE1 • Sponsor: Alterome Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug INV-8989 targets Hard-to-Treat cancers with KRAS G12D mutation
Disease control Recruiting nowThis study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 178 adults with cancers …
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could early rectal cancer patients skip radiation? new trial aims to find out
Disease control Recruiting nowThis study tests whether giving chemotherapy alone before limited surgery works as well as chemotherapy plus radiation for early rectal cancer. The goal is to see if avoiding radiation improves quality of life without harming cancer control. About 250 adults with early-stage rect…
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for tough colorectal cancer: LYL273 trial opens
Disease control Recruiting nowThis study tests a new drug, LYL273, in about 155 adults with metastatic colorectal cancer that has relapsed or stopped responding to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. Participants must have limited liver involvement and no surg…
Phase: PHASE1, PHASE2 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
CHEMO-FREE HOPE: new trial tests skipping Post-Surgery drugs for colorectal cancer
Disease control Recruiting nowThis study is looking at whether people with locally advanced colorectal cancer who have already received chemotherapy or radiation before surgery can safely skip additional chemotherapy afterward. The trial will compare a 'wait and watch' approach to standard adjuvant chemothera…
Phase: NA • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Can chemo before surgery clear rectal cancer and liver tumors?
Disease control Recruiting nowThis study looks at whether giving FOLFIRINOX chemotherapy before surgery helps people with mid or lower rectal cancer that has spread to the liver. The goal is to see if both the rectal tumor and liver spots can be completely removed. About 550 adults will take part, and the mai…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for hard-to-treat colon cancer? trial launches for MSS patients.
Disease control Recruiting nowThis study tests if a new combination of drugs (DSP107 and atezolizumab) works better than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). About 90 adults who have already tried other therapies will be randomly …
Phase: PHASE2 • Sponsor: Kahr Bio Australia Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Virus therapy takes on tough colorectal cancer in new trial
Disease control Recruiting nowThis study tests whether adding a virus-based drug (pelareorep) to standard chemotherapy can help people with a specific type of advanced colorectal cancer that has stopped responding to initial treatment. About 60 adults whose cancer has spread and has certain genetic features (…
Phase: PHASE2 • Sponsor: Oncolytics Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study is testing an experimental oral drug, VVD-133214, in people with advanced solid tumors that have specific genetic features (MSI or dMMR). The drug works by blocking a protein that helps these cancers grow. The study will check safety and how well the drug w…
Phase: PHASE1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New antibody drug targets HER2 cancers in broad trial
Disease control Recruiting nowThis phase 2 trial tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers, including breast, lung, stomach, and others. Participants have already tried at least one standard treatment. The study measures how many tumors shrink or disappear. Zanida…
Phase: PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New antibody drug ADCX-020 enters first human trials for advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called ADCX-020 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody drug conjugate designed to deliver cancer-killing agents directly to tumor cells. The study will first find th…
Phase: PHASE1 • Sponsor: Adcytherix SAS • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
CtDNA test guides chemo to stop rectal cancer return
Disease control Recruiting nowThis study tests whether giving chemotherapy after surgery can prevent rectal cancer from returning in people who have a positive ctDNA blood test (a sign of leftover cancer cells). About 103 adults with high-risk rectal cancer will either receive chemo or be observed. The goal i…
Phase: PHASE3 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Heated chemo during surgery could boost colon cancer survival
Disease control Recruiting nowThis phase 3 trial is testing whether giving chemotherapy before surgery, with or without a heated chemotherapy wash inside the abdomen during surgery, can help people with locally advanced colon cancer live longer without the cancer returning. About 1,083 participants will be ra…
Phase: PHASE3 • Sponsor: Maimónides Biomedical Research Institute of Córdoba • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug targets hidden cancer cells after colorectal cancer treatment
Disease control Recruiting nowThis phase 2 trial tests the drug AMB-05X in 15 colorectal cancer patients who have completed curative treatment but still have signs of cancer in their blood (ctDNA-positive) with no visible tumors on scans. The goal is to see if the drug can safely eliminate these remaining can…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Supercharged immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment made from specially engineered immune cells (T cells) donated by healthy people. The cells are designed to better recognize and kill cancer cells while lasting longer in the body. The trial includes 24 adults with blood cancers or solid tumors tha…
Phase: PHASE1, PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug targets rare genetic cancers in early trial
Disease control Recruiting nowThis study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…
Phase: PHASE1, PHASE2 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New cancer drug enzelkitug enters first human trials
Disease control Recruiting nowThis early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New vaccine shows promise in early trial for tough cancers
Disease control Recruiting nowThis early-stage study tests a new type of cancer vaccine made from irradiated tumor and nearby cells. It aims to see if the vaccine is safe and can help the immune system fight advanced solid tumors like osteosarcoma, pancreatic cancer, and others. About 54 people will take part…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New radiation therapy targets Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis early-stage study is testing a new treatment for people with metastatic colorectal cancer that has stopped responding to standard therapies. The treatment uses a two-step process to deliver a radioactive particle directly to cancer cells, aiming to control the disease. About…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New chemo injection targets tumors directly in early trial
Disease control Recruiting nowThis early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…
Phase: PHASE1 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New pill targets Hard-to-Treat cancers with a specific gene mutation
Disease control Recruiting nowThis study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
AI-Powered blood test could spot five cancers before symptoms show
Diagnosis Recruiting nowThis study is testing a new blood test called EXoPred that uses artificial intelligence and laser technology to find tiny particles from cancer cells. The goal is to detect breast, colon, pancreatic, ovarian, and lung cancers at an early stage. Researchers will enroll 1,400 peopl…
Sponsor: EXoPERT • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New blood test could spot 10 cancers before symptoms start
Diagnosis Recruiting nowThis study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
Blood test could spare thousands from unneeded colonoscopies
Diagnosis Recruiting nowThis study investigates whether a blood test can help identify people who have a positive stool test for hidden blood but are actually at very low risk for colorectal cancer. The goal is to reduce the number of unnecessary colonoscopies, which are invasive and strain healthcare r…
Sponsor: Vejle Hospital • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
New PET tracers aim to light up Hard-to-See cancers
Diagnosis Recruiting nowThis early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to co…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New scan technique could sharpen tumor targeting during radiation
Diagnosis Recruiting nowThis study tests whether a special CT scan with contrast dye can give clearer images of tumors during radiation therapy. Twenty adults with advanced cancer will receive the extra scan alongside their standard treatment. The goal is to see if this approach is feasible and improves…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New imaging tracer could spot tumors more clearly
Diagnosis Recruiting nowThis early-stage study tests a new injection called [18F]LY4214835 to see if it is safe and how it spreads in the body. It includes healthy volunteers and people with cancer. The goal is to improve how doctors see tumors using imaging scans.
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
AI eye on cancer: robot helps spot hidden polyps
Diagnosis Recruiting nowThis study will test whether artificial intelligence (AI) can help doctors find and identify colorectal polyps during colonoscopy better than standard methods. About 1000 adults having a routine colonoscopy will be randomly assigned to either AI-assisted or standard colonoscopy. …
Phase: NA • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
Can a quick scope after surgery prevent dangerous leaks?
Diagnosis Recruiting nowThis trial is testing whether doing a colonoscopy 5 to 8 days after low colorectal cancer surgery can help doctors spot anastomotic leaks earlier than standard monitoring. About 140 adults who had surgery for colorectal cancer will either get an early colonoscopy or routine care.…
Phase: NA • Sponsor: Nanchong Central Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New PET tracer could sharpen cancer detection
Diagnosis Recruiting nowThis study tests a new radioactive tracer called [18F]FPyQCP for PET scans to see if it can better detect several cancers, including colorectal, ovarian, gastric, breast, and pancreatic. About 71 adults with these cancers will receive the tracer and have a PET/CT scan. The goal i…
Phase: PHASE1, PHASE2 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
New blood test could spot colon cancer before it spreads
Diagnosis Recruiting nowThis study is testing a new blood test called DENEB that looks for tiny molecules (microRNAs) to find colorectal cancer and precancerous polyps early. Researchers will collect blood samples from 2,000 people who are also getting a colonoscopy. The goal is to see if the blood test…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New scan could spot hidden cancers in the belly
Diagnosis Recruiting nowThis study tests a new PET/CT scan using a radioactive tracer called GEH300079 to detect peritoneal carcinomatosis—cancer that has spread to the lining of the abdomen—in people with colorectal, stomach, ovarian, or pancreatic cancer. About 175 adults with known or suspected sprea…
Phase: PHASE2, PHASE3 • Sponsor: GE Healthcare • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Heartbeat clues may spot hidden surgical dangers
Diagnosis Recruiting nowThis study explores whether measuring heart rate variability—the natural ups and downs in heartbeat timing—can help detect complications like leaks or abscesses after planned colorectal surgery. Researchers will monitor patients for a week after surgery and compare heart rate pat…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Pee test could spot colon cancer early in africa
Diagnosis Recruiting nowThis study is testing a new urine test that aims to detect colorectal cancer and precancerous polyps early. Researchers will enroll 210 people in Ghana, Tanzania, and South Africa who have symptoms like rectal bleeding or are getting a colonoscopy. The test uses a biosensor to fi…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Could a menstrual cup replace painful biopsies for cancer screening?
Diagnosis Recruiting nowThis study looks at whether a menstrual cup can collect enough uterine tissue to screen for endometrial cancer, especially in women with Lynch syndrome who are at higher risk. About 25 participants will use a menstrual cup at home and also have a standard biopsy, then compare the…
Phase: NA • Sponsor: Jessica D. St. Laurent, MD • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
Can you wait 10 years? new study tests longer colonoscopy intervals for Low-Risk polyps
Prevention Recruiting nowThis study looks at whether people who have had 1 or 2 small, non-cancerous polyps removed can safely wait 10 years for their next colonoscopy instead of the usual 5 years. About 9,500 adults aged 45-69 will be randomly assigned to one of two schedules: a colonoscopy at 5 and 10 …
Phase: NA • Sponsor: NRG Oncology • Aim: Prevention
Last updated Jul 03, 2026 23:00 UTC
-
Diet study tests if plants beat cancer risk
Prevention Recruiting nowThis study tests whether eating more plants and fewer animal foods can lower colorectal cancer risk. Researchers will measure changes in bile acids, gut bacteria, and other markers in 40 adults who have had colon polyps removed. Participants follow a self-guided diet for several …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Mouthwash may stop chemo mouth sores in their tracks
Prevention Recruiting nowThis study tests whether a dexamethasone mouthwash can prevent moderate to severe mouth sores caused by chemotherapy in adults with cancer. Participants use the mouthwash four times daily during chemo for up to 8 weeks. Researchers compare their outcomes to a historical group to …
Phase: PHASE4 • Sponsor: Woman's • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Cooling sleeve could shield cancer patients from chemo nerve pain
Prevention Recruiting nowThis study tests a special cooling and compression sleeve (Paxman Limb Cryocompression System) worn during chemotherapy to prevent nerve damage, a common side effect. About 200 cancer patients receiving weekly paclitaxel will use the device for up to 4 hours per session. Research…
Phase: NA • Sponsor: National University Hospital, Singapore • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Could a Cancer-Killing pill stop colon cancer before it starts?
Prevention Recruiting nowThis early-phase study tests the safety of a drug called ONC201 (dordaviprone) in 36 adults at high risk for colorectal cancer due to familial adenomatous polyposis (FAP) or a history of many polyps. The drug aims to kill precancerous cells without harming normal ones. Researcher…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 27, 2026 13:07 UTC
-
Cheap statin could slash deadly clot risk in cancer patients
Prevention Recruiting nowThis study tests whether taking a daily statin (rosuvastatin) for one year can safely prevent life-threatening blood clots in people with cancer. Current clot-preventing drugs raise bleeding risks, so a safer option is needed. The trial will enroll 4,000 adults with newly diagnos…
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
Online resilience training aims to ease anxiety in advanced cancer
Symptom relief Recruiting nowThis study tests a virtual group program designed to help people with advanced cancer build resilience and manage stress, anxiety, and fatigue. Participants attend seven weekly online sessions that teach techniques like mindfulness, gratitude, and reframing difficult experiences.…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
New algorithm aims to keep chemo on track for stomach and colon cancers
Symptom relief Recruiting nowThis study tests whether a special algorithm called PAGODA can reduce unplanned delays during FOLFOX chemotherapy for gastrointestinal cancers like colon, stomach, and esophageal cancer. About 420 participants will be randomly assigned to either standard care or the algorithm-gui…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
Home workouts via video calls could ease cancer side effects
Symptom relief Recruiting nowThis study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
Cancer patients' values take center stage in new nurse-led program
Symptom relief Recruiting nowThis study adapts a program called CONVO for Spanish-speaking Latinx adults with solid tumors. In the program, nurses talk with patients about their personal values during routine cancer care. The goal is to make care more respectful and supportive. About 234 adults will take par…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
Which meditation works best for cancer survivors? a new study aims to find out
Symptom relief Recruiting nowThis pilot study explores how four different meditation practices—breathing only, focused attention only, mindfulness only, and a combination of all three—affect relaxation in cancer survivors. Many cancer patients experience stress and anxiety, and meditation may help reduce dis…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Can a smartphone app ease cancer Survivors' stress? new trial aims to find out
Symptom relief Recruiting nowThis study tests whether a smartphone app that teaches mindfulness can help reduce stress in people who have finished cancer treatment. About 345 cancer survivors will be randomly assigned to use the app right away or wait three months. The goal is to see if the app makes a real …
Phase: NA • Sponsor: Canadian Cancer Trials Group • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Yoga and mindfulness may help cancer survivors heal from within
Symptom relief Recruiting nowThis study tests whether yoga and mindfulness programs can improve quality of life, reduce inflammation, and even affect gene activity in people who have survived lung, colon, or non-Hodgkin's lymphoma cancer. One hundred survivors, at least six months past treatment, will be ran…
Phase: NA • Sponsor: Barbara Nemesure • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Virtual reality offers escape for bone marrow transplant patients
Symptom relief Recruiting nowThis study tests whether using virtual reality (VR) can improve symptoms like pain, anxiety, and fatigue in patients receiving a bone marrow transplant. About 28 adults will be randomly assigned to either VR sessions or standard care during their hospital stay. The goal is to see…
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
New app aims to make End-of-Life conversations easier for cancer patients
Symptom relief Recruiting nowThis study tests a mobile app called PACT that helps people with advanced cancer talk about and plan the care they would want if they couldn't speak for themselves. The app involves patients and their loved ones in these discussions. Researchers want to see if the app is easy to …
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Could eating only during daylight hours improve cancer treatment?
Symptom relief Recruiting nowThis study tests whether eating only within an 8-hour window (time-restricted eating) can improve how well cancer treatments work and reduce side effects. It involves 100 Alaska Native and American Indian patients with breast or rectal cancer. Participants will follow the eating …
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Can phone Check-Ins ease cancer treatment side effects?
Symptom relief Recruiting nowThis study tests whether regular phone check-ins and counseling can help people on oral cancer drugs feel better and avoid hospital visits. 600 patients will be assigned to symptom monitoring alone, or monitoring plus a self-help handbook and phone counseling for anxiety or sadne…
Phase: NA • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New pill aims to stop chemo sickness in its tracks
Symptom relief Recruiting nowThis study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Virtual meditation may ease cancer stress in rural areas
Symptom relief Recruiting nowThis pilot study tests whether a virtual mindfulness-based stress reduction (MBSR) program can improve mental health in cancer patients living in underserved or rural parts of Minnesota. About 45 participants will take the online course and report changes in stress, anxiety, and …
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Can a special diet soothe chemo nerve damage?
Symptom relief Recruiting nowThis study tests whether a diet low in added sugar, high in fiber, and rich in omega-3s (called LASO-3) can help reduce nerve pain, numbness, and tingling caused by chemotherapy. Fifty cancer survivors who finished chemo at least three months ago will receive virtual nutrition co…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Can a herbal capsule beat cancer fatigue? new trial aims to find out
Symptom relief Recruiting nowThis phase 3 trial tests whether Nuvastatic 300mg, a herbal supplement, can reduce cancer-related fatigue in adults with metastatic colorectal cancer who are receiving standard chemotherapy. About 250 participants will take either Nuvastatic or a placebo three times daily for abo…
Phase: PHASE3 • Sponsor: Natureceuticals Sdn Bhd • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Can a herbal sachet beat chemo fatigue? new trial aims to find out
Symptom relief Recruiting nowThis Phase 3 study tests whether Nuvastatic, a herbal supplement taken as a powder sachet three times daily, can reduce cancer-related fatigue in adults with stage IV colon cancer who are starting chemotherapy. About 180 participants will receive either Nuvastatic or a placebo fo…
Phase: PHASE3 • Sponsor: Natureceuticals Sdn Bhd • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Can a Culturally-Tailored therapy reduce anxiety in advanced cancer patients?
Symptom relief Recruiting nowThis study tests whether a therapy called Meaning-Centered Psychotherapy for Latinos (MCP-L) can help reduce anxiety and depression in 300 Latino patients with advanced cancer. Participants receive either MCP-L or standard cognitive behavioral therapy over about 3 months. The goa…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Can walking during chemo reduce side effects? new study aims to find the best dose
Symptom relief Recruiting nowThis study is testing three different amounts of treadmill walking (90, 150, or 300 minutes per week) in people receiving chemotherapy for colorectal or stomach cancers. The goal is to find a safe and practical exercise level that helps patients complete their full chemotherapy p…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Can a phone or video chat lift depression in older cancer survivors?
Symptom relief Recruiting nowThis study tests whether a type of talk therapy called behavioral activation (BA) can help treat depression in older adults who have survived cancer. Participants will receive BA or supportive psychotherapy remotely via video or phone over 10 weeks. The goal is to see if BA reduc…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
New telehealth program aims to ease the burden of advanced cancer for patients and families
Symptom relief Recruiting nowThis study tests a program called BOLSTER, which offers six telehealth sessions with a nurse to help patients with advanced gynecologic or gastrointestinal cancers and their care partners build skills, manage symptoms, and cope with challenges. Participants also get access to a w…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Money worries in cancer care: new program aims to keep patients on track
Symptom relief Recruiting nowThis study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Weighted blankets may ease anxiety for cancer patients during IV therapy
Symptom relief Recruiting nowThis study looks at whether using a weighted blanket during intravenous cancer treatment can help lower anxiety, stress, and depression, and improve comfort. About 152 adults with solid cancers who are starting their first IV therapy will be randomly assigned to receive either a …
Phase: NA • Sponsor: Sultan Qaboos Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New support program hopes to ease Cancer's toll on chinese patients
Symptom relief Recruiting nowThis study tests a support program for Chinese cancer patients and survivors that includes education sessions, counseling, and peer support. The program is delivered by phone or video call. Researchers want to see if the program is practical and whether it improves quality of lif…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Hearing loss shield: new drug may protect ears during chemo
Symptom relief Recruiting nowThis study tests a drug called Pedmark (sodium thiosulfate) to see if it can prevent hearing loss in adults receiving cisplatin chemotherapy for cancers like testicular, head and neck, or thoracic cancer. About 25 adults will take Pedmark alongside their chemo. The drug is alread…
Phase: PHASE1, PHASE2 • Sponsor: University of Arizona • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to stop cancer wasting
Symptom relief Recruiting nowThis Phase 2 trial tests a drug called ASCA101 in 135 adults with solid tumors (colorectal, ovarian, or lung cancer) who have cachexia—a condition causing severe weight loss and muscle wasting. Participants receive either ASCA101, an active control (Megace), or a placebo for 12 w…
Phase: PHASE2 • Sponsor: MetaFines • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could a nurse-led online therapy beat severe fatigue in advanced cancer?
Symptom relief Recruiting nowThis trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…
Phase: NA • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New scope procedure vs. surgery: which unblocks the stomach faster?
Symptom relief Recruiting nowThis study compares a newer, less invasive endoscopic procedure to standard surgery for treating gastric outlet obstruction, a blockage that prevents food from leaving the stomach. The trial will enroll 32 adults with advanced cancers causing this blockage. The main goal is to se…
Phase: NA • Sponsor: Northwell Health • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New study trains therapists to tackle Cancer's hidden toll: anxiety, pain, and insomnia
Symptom relief Recruiting nowThis study aims to train psychotherapists to deliver personalized, evidence-based therapies to cancer patients and their caregivers who are experiencing high levels of distress. Therapists will choose from treatments like cognitive behavioral therapy and mindfulness-based stress …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Cancer care goes home: study tests nurse visits to cut hospital trips
Symptom relief Recruiting nowThis study is testing a new way to manage care for 33 cancer patients who take oral chemotherapy at home. Instead of going to the hospital every month just to pick up medicine, a nurse will visit them at home twice in six months. An advanced practice nurse will coordinate everyth…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New app aims to ease cancer distress
Symptom relief Recruiting nowThis study tests whether a mobile app called Tools for Coping with Cancer can help people with a history of cancer reduce distress and improve mood and quality of life. About 50 adults who have had cancer will use the app at home for 8 weeks and fill out questionnaires about thei…
Phase: NA • Sponsor: Yale University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can a smartphone app lift depression in cancer survivors?
Symptom relief Recruiting nowThis study compares two ways to treat depression in cancer survivors: a mobile app called Moodivate that tracks activities and mood, and 8 sessions of telehealth therapy with a mental health provider. About 45 adults who have had cancer and currently feel depressed will take part…
Phase: NA • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Fish oil and band workouts: a new hope against cancer muscle loss?
Symptom relief Recruiting nowThis study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…
Phase: NA • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New shot aims to reverse cancer wasting
Symptom relief Recruiting nowThis early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…
Phase: PHASE1 • Sponsor: Kexing Biopharm Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New support program aims to help cancer patients finish treatment and feel better
Symptom relief Recruiting nowThis study tests a program called ICCAN that gives cancer patients extra help with social and economic needs, like finding resources and monthly check-ins. Researchers want to see if this support helps patients complete their cancer treatment and improves their quality of life, c…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Squeeze away chemo pain: gloves and boots may stop nerve damage
Symptom relief Recruiting nowThis study tests special gloves and boots that gently squeeze the hands and feet during chemotherapy. The pressure may reduce how much chemo reaches the nerves, possibly preventing pain and numbness. About 142 adults with cancer will try the devices to see if they help avoid nerv…
Phase: NA • Sponsor: Luminate Medical, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Tailored training may boost healthy living in GI cancer survivors
Symptom relief Recruiting nowThis study tests whether personalized self-management training helps people with gastrointestinal cancer adopt healthier habits like better diet and more exercise. 120 participants will be randomly assigned to either personalized or standard training for 6 weeks. The goal is to s…
Phase: NA • Sponsor: University of Southern California • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Could a simple nerve stimulator fix bowel leakage after rectal cancer surgery?
Symptom relief Recruiting nowThis study tests whether a small nerve stimulator placed on the skin near the ankle can help people who have bowel leakage after rectal cancer surgery. Half of the 84 participants will use the active device at home, while the other half will use a sham device. Researchers will ch…
Phase: NA • Sponsor: Althaia Xarxa Assistencial Universitària de Manresa • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New program aims to smooth cancer Patients' return home
Symptom relief Recruiting nowThis study tests a program to help cancer patients transition from hospital to home. It includes a meeting with a nurse before leaving, an app to report symptoms, and a follow-up phone call. The goal is to see if this approach is feasible and improves patient satisfaction and qua…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New program aims to ease tough End-of-Life talks for cancer patients
Symptom relief Recruiting nowThis study tests a program called ROCKS that helps people with advanced cancer and their family caregivers build optimism, communication skills, and knowledge to discuss advance care planning. 152 patient-caregiver pairs will be randomly assigned to the ROCKS program or usual car…
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New program aims to boost resilience in young cancer patients
Symptom relief Recruiting nowThis study is testing a support program for teens and young adults (ages 16-30) who have just been diagnosed with cancer. The program includes a meeting with a special team and a structured course called PRISM that teaches skills like stress management and goal setting. About 130…
Phase: NA • Sponsor: Karolinska Institutet • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New radiation technique may ease cancer bone pain better than standard therapy
Symptom relief Recruiting nowThis phase 3 trial tests whether a precise, high-dose radiation technique (SBRT) provides better pain relief than standard radiation for cancer patients with painful bone metastases not in the spine. About 230 adults with solid tumors and moderate to severe pain will be randomly …
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Cactus extract could zap cancer pain in new trial
Symptom relief Recruiting nowThis early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…
Phase: PHASE1 • Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Cancer patients may soon get immunotherapy at home instead of the clinic
Symptom relief Recruiting nowThis study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can talking about stress ease Cancer's mental toll? new study aims to find out
Symptom relief Recruiting nowThis study tests whether group sessions that teach stress management skills can lower distress in people with cancer. About 400 adults with cancer who have moderate distress will take part. The program helps patients recognize and reduce stress in their daily lives.
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
VR gives hospitalized kids with cancer a fun way to get moving
Symptom relief Recruiting nowThis study tests whether virtual reality (VR) can help children and young adults with cancer be more physically active while in the hospital. 40 participants aged 10-25 will try both VR-assisted physical therapy and traditional physical therapy to see which one gets them moving m…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Chatbot vs. standard care: which boosts genetic testing in young cancer patients?
Knowledge-focused Recruiting nowThis study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Who should tell relatives about cancer risk? new study tests best approach
Knowledge-focused Recruiting nowThis study looks at whether having a healthcare provider directly contact close relatives of people with newly diagnosed colorectal cancer leads to more genetic testing than having the patient share the information themselves. About 4,186 patients and their relatives will take pa…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Radiation aftermath: 700 cancer patients tracked for decades
Knowledge-focused Recruiting nowThis study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists try to personalize heated chemo for stomach cancers
Knowledge-focused Recruiting nowThis study looks at a treatment called HIPEC, where heated chemotherapy is washed inside the abdomen after surgery to remove tumors. Researchers want to see if lab-grown tumor models can predict how well the chemotherapy works. Sixty adults with cancers that have spread to the ab…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
New biobank aims to unlock secrets of Immunotherapy's harsh side effects
Knowledge-focused Recruiting nowThis study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Personalized care plans aim to boost resilience in seniors on chemo
Knowledge-focused Recruiting nowThis study looks at how to better support adults aged 65 and older during chemotherapy. Researchers will use a frailty score to create personalized care plans and track how well participants handle treatment. The goal is to see if this approach improves resilience and reduces hos…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
New robot arm takes on cancer surgery – first safety check begins
Knowledge-focused Recruiting nowThis study will test a new robotic surgery platform called RonovoTM in 40 adults with cancer who need elective surgery. The robot helps surgeons perform minimally invasive procedures in digestive, thoracic, urology, and gynecology areas. Researchers will track complications, tech…
Phase: NA • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists launch massive tumor repository to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
New online tool aims to ease financial burden for cancer patients
Knowledge-focused Recruiting nowThis study is testing a web-based tool called CARE that gives cancer patients information about treatment costs, health insurance, and financial resources. About 430 adults with gynecologic, prostate, lung, or colorectal cancer will use the tool to see if it helps them feel more …
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Scientists hunt for clues to prevent a common complication after pancreatic cancer surgery
Knowledge-focused Recruiting nowThis study looks at 100 people who have had a Whipple procedure (pancreaticoduodenectomy) for cancers of the pancreas or nearby areas. The goal is to find factors before, during, and after surgery that raise the risk of a pancreatic fistula—a leak of digestive fluid that can caus…
Phase: NA • Sponsor: Minia University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Can lower doses of immunotherapy be safer without losing effectiveness?
Knowledge-focused Recruiting nowThis study looks at whether giving a lower dose of immunotherapy (pembrolizumab or nivolumab) causes fewer serious side effects than the standard higher dose. About 192 adults with solid tumors will be randomly assigned to receive either the higher or lower dose. The main goal is…
Phase: PHASE3 • Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Cancer survivors may carry hidden aging markers that raise disease risk
Knowledge-focused Recruiting nowThis study will compare levels of fatty acid binding proteins and cellular aging markers in 120 cancer survivors versus people who never had cancer. Researchers want to see if these markers are higher in survivors and linked to conditions like diabetes and high blood pressure. Pa…
Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New approach aims to make repeat radiation safer for cancer patients
Knowledge-focused Recruiting nowThis study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Blood test may replace scans for some colorectal cancer patients on immunotherapy
Knowledge-focused Recruiting nowThis study is looking at whether a simple blood test that tracks tumor DNA (ctDNA) can better predict how well immunotherapy is working in people with advanced colorectal cancer. Currently, doctors rely on imaging scans, which can miss cases where the cancer is actually gone. The…
Sponsor: Geneplus-Beijing Co. Ltd. • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New study aims to better understand what matters most to young cancer patients
Knowledge-focused Recruiting nowThis study asks 3000 teens and young adults (ages 15-39) with cancer, along with their caregivers, to answer survey questions about body image, fertility, and financial stress. The goal is to create better tools to measure quality of life for future patients. Participants include…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Thousands of cancer patients enrolled in massive immunotherapy observation study
Knowledge-focused Recruiting nowThis study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Massive proton therapy registry aims to unlock secrets of cancer treatment
Knowledge-focused Recruiting nowThis registry collects detailed information from cancer patients treated with proton radiation therapy. Researchers will track treatment plans, side effects, and quality of life over 15 years. The goal is to learn which patients benefit most from this precise form of radiation an…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Scientists seek cancer samples to unlock immune secrets
Knowledge-focused Recruiting nowThis study collects blood and tumor samples from people with gastrointestinal cancers, such as stomach, liver, or colon cancer. Researchers want to learn how the immune system responds to these cancers. Participants give samples over several visits but receive no treatment as par…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New program aims to boost cancer trial enrollment from under 5%
Knowledge-focused Recruiting nowThis study tests a Clinical Trials Navigator program that helps cancer patients, families, and doctors find and enroll in clinical trials outside their local cancer centre. The program will be rolled out to 20 centres across Canada, starting with Thunder Bay and Winnipeg. Researc…
Phase: NA • Sponsor: Windsor Regional Hospital • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Bacteria in the mouth and gut may predict who responds to cancer immunotherapy
Knowledge-focused Recruiting nowThis study looks at the bacteria living in the mouth, stool, and tumors of Colombian adults with advanced cancers of the stomach, colon, breast, cervix, or head and neck who are starting immunotherapy as standard care. Researchers will compare these microbial profiles to those of…
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a simple blood test predict leukemia risk after cancer therapy?
Knowledge-focused Recruiting nowThis study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Could your genes hold the key to cancer risk? scientists investigate families
Knowledge-focused Recruiting nowThis study looks at genetic and behavioral factors that might influence cancer development and outcomes. It involves people with a personal or family history of cancer, who provide samples like blood, saliva, or urine. The goal is to better understand inherited cancer risks and f…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Blood test may guide cancer care without biopsy
Knowledge-focused Recruiting nowThis study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…
Phase: NA • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Massive cancer database aims to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Live biopsy study aims to predict immunotherapy response in cancer patients
Knowledge-focused Recruiting nowThis study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Scientists dig into DNA of rare gut cancer to improve prognosis
Knowledge-focused Recruiting nowThis study looks at stored tumor samples from 400 people with appendiceal cancer. Researchers will analyze DNA and RNA modifications to find patterns linked to how the cancer behaves. The goal is to create a molecular score that could one day help doctors predict outcomes more ac…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Cancer Patients' supplement use under the microscope
Knowledge-focused Recruiting nowThis observational study will survey 1,000 cancer patients about their use of dietary supplements like vitamins, minerals, and herbal products. Researchers want to know how common supplement use is, whether patients experience side effects, and if these supplements could interact…
Sponsor: Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Mini tumors in a dish could pick the right drug for stubborn cancers
Knowledge-focused Recruiting nowThis study is testing whether growing a patient's tumor cells in the lab (as 3D 'organoids') can help doctors pick the best drug for advanced cancers that have stopped responding to standard treatments. About 152 adults with colorectal or pancreatic cancer will have a biopsy to c…
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Blood test may predict dangerous side effects of cancer immunotherapy
Knowledge-focused Recruiting nowThis observational study is looking at whether certain markers in the blood can predict immune-related side effects in cancer patients receiving immunotherapy. Researchers will collect blood samples and health data from 200 participants during routine visits. The goal is to bette…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New italian tool aims to ease MRI anxiety for cancer patients
Knowledge-focused Recruiting nowThis study is translating and testing an Italian version of a questionnaire that measures anxiety in cancer patients during whole-body MRI scans. Researchers will enroll 175 adult cancer patients at the European Institute of Oncology. The goal is to ensure the Italian version is …
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Massive cancer study aims to unlock tumor secrets and speed up trials
Knowledge-focused Recruiting nowSPECTA is a large research platform that collects tumor samples, genetic data, and patient information from nearly 5,000 people with all types of cancer. The goal is to help scientists better understand cancer biology and find new ways to match patients with the right clinical tr…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Can a culturally tailored online program get more black cancer survivors tested for genetic risks?
Knowledge-focused Recruiting nowThis study aims to help African American cancer survivors learn about and get genetic testing for hereditary cancer risks. Researchers are adapting an online educational program to be culturally relevant, with input from community leaders and genetics experts. About 85 participan…
Phase: NA • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Can a smartwatch help track cancer symptoms? small study aims to find out
Knowledge-focused Recruiting nowThis study is testing whether people in early-phase cancer trials will consistently wear a smartwatch and complete weekly symptom surveys on a phone app. Thirty participants will use the devices for 4 weeks. The goal is to see if this approach is practical and acceptable, not to …
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Mayo clinic turns blood into stem cells to predict chemo side effects
Knowledge-focused Recruiting nowThis Mayo Clinic study is collecting blood samples from 30 cancer patients to create personalized stem cell models. The goal is to understand why some people have severe side effects from cancer therapy while others do not. This is a non-interventional study, meaning no new treat…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Tiny study tracks cancer Drug's journey through the body
Knowledge-focused Recruiting nowThis early-stage study looks at how the experimental drug saruparib is absorbed, distributed, and eliminated in 8 people with advanced solid tumors. Participants will receive the drug by mouth and by vein, with samples taken to track the drug and its breakdown products. The goal …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Can a smartphone app ease the stress of cancer genetic testing?
Knowledge-focused Recruiting nowThis study tests a digital app called the Genetics Adviser for Mainstream Care (GA-Mainstream) that educates cancer patients about genetic testing and delivers their results. Researchers want to see if using the app reduces distress and improves the patient experience compared to…
Phase: NA • Sponsor: Unity Health Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study checks how liver issues affect cancer drug pelabresib
Knowledge-focused Recruiting nowThis early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New PET imaging study aims to sharpen tumor detection
Knowledge-focused Recruiting nowThis study is collecting data from 2,000 adults with solid tumors who undergo theranostic PET scans as part of their routine care. The goal is to see how well these scans detect tumors and match with lab results, which could help doctors make better treatment decisions. Participa…
Sponsor: University Hospital, Essen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New online tool aims to keep cancer survivors on track with Follow-Up care
Knowledge-focused Recruiting nowThis study tests an online portal called SCP-PHR designed to help colon and rectal cancer survivors manage their survivorship care. Researchers will enroll 250 adults who have completed initial treatment within the past year. The goal is to see if the portal improves how often su…
Phase: NA • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study checks cancer Drug's effect on common medications
Knowledge-focused Recruiting nowThis study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Microchip implanted in liver tumors could personalize cancer treatment
Knowledge-focused Recruiting nowThis early-phase study tests a small implantable device placed directly into liver tumors from colorectal cancer. The device releases tiny amounts of several chemotherapy and immunotherapy drugs to see how the tumor responds. After a few days, the device is removed along with the…
Phase: EARLY_PHASE1 • Sponsor: Northwell Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can a simple text message save lives? new study aims to boost colon cancer screening
Knowledge-focused Recruiting nowThis study aims to find the best text messages to remind people to complete at-home colorectal cancer screening. Researchers will work with 7,220 adults aged 45-75 at community health centers. They will test different message versions to see which ones lead to more screening and …
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Cancer pill makeover may mess with treatment adherence
Knowledge-focused Recruiting nowThis study follows 334 cancer patients to see if switching between different-looking generic chemo pills affects their adherence and health outcomes. Researchers will track pill counts and patient surveys over six months. The goal is to understand if changes in pill color, shape,…
Sponsor: Universidad Miguel Hernandez de Elche • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Lynch syndrome study seeks to uncover hidden skin cancer link
Knowledge-focused Recruiting nowThis study aims to find out how often Muir-Torre syndrome (MTS) occurs in people who already have Lynch syndrome, a genetic condition that raises cancer risk. Researchers will examine skin lesions and tumors from 150 participants to see if they are linked to MTS. The goal is to b…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can a simple blood test tell who needs more cancer treatment?
Knowledge-focused Recruiting nowThis study is testing whether a blood test that looks for cancer DNA (called a liquid biopsy) can find leftover cancer cells after surgery in people with stage III colorectal cancer. The goal is to see if this test can help doctors decide who needs additional treatment and who ca…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to uncover why some women have worse sexual side effects from radiation
Knowledge-focused Recruiting nowThis study is observing 300 women with female sexual organs who are receiving radiotherapy for certain cancers. Researchers want to understand why some patients have more sexual side effects than others. They will track sexual quality of life and look at radiation doses to find p…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Personalized chemo test aims to improve treatment for advanced abdominal cancers
Knowledge-focused Recruiting nowThis study tests a new method called mass-based response testing (MRT) to help doctors choose the best chemotherapy drugs for patients with advanced appendix or colorectal cancer that has spread to the abdomen. The MRT device analyzes live tumor cells to see which drugs work best…
Phase: NA • Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can a simple blood test tell if cancer is really gone?
Knowledge-focused Recruiting nowThis study is testing whether a blood test that looks for cancer DNA (called ctDNA) can find leftover cancer cells after surgery in people with colorectal cancer that has spread to the liver. The goal is to see which test works best at predicting if the cancer will come back. Thi…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Gene-Guided cancer therapy: a new hope for advanced tumors?
Knowledge-focused Recruiting nowThis study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…
Sponsor: Seoul National University Bundang Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Hunt for hidden cancer genes: families needed to unlock hereditary secrets
Knowledge-focused Recruiting nowThis study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New toolkit aims to fix cancer trial diversity gap
Knowledge-focused Recruiting nowThis study tests a program called SUPPORT that helps Black and Latino cancer patients learn about and join clinical trials. The program includes a website and a navigator who guides patients. Researchers will see if this increases the number of patients referred to and enrolled i…
Phase: NA • Sponsor: Eastern Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists gather tumor samples to unlock new cancer treatments
Knowledge-focused Recruiting nowThis study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New scan could predict rectal cancer treatment success early
Knowledge-focused Recruiting nowThis study is testing whether special PET-MRI scans can predict how well rectal cancer responds to chemotherapy and radiation before surgery. Researchers will scan 50 patients multiple times during treatment to see if early changes in the tumor can forecast the final outcome. The…
Sponsor: Centre Paul Strauss • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to make allergy testing safer for cancer patients on biologics
Knowledge-focused Recruiting nowThis study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple blood test predict who responds to immunotherapy?
Knowledge-focused Recruiting nowThis study from Mayo Clinic is looking at how T cells (a type of immune cell) change during anti-PD-1 immunotherapy in people with advanced melanoma, lung cancer, or other solid tumors. Researchers will collect blood and tissue samples from 500 participants to measure specific ma…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Decoding Immunotherapy's liver side effect to keep cancer treatment on track
Knowledge-focused Recruiting nowThis study looks at liver inflammation (hepatitis) that can occur in cancer patients treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers aim to describe the different patterns of liver injury and how they respond to treatment. By collecting real-world …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
What happens when your genes reveal a surprise? new study seeks answers.
Knowledge-focused Recruiting nowThis study looks at people who have a gene variant (called a secondary finding) that was found during genetic testing for another reason. Researchers want to understand how these variants affect health, how people respond to the news, and whether they follow medical advice. Up to…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Choice or fixed? study tests how to get better data from young cancer patients
Knowledge-focused Recruiting nowThis study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…
Phase: NA • Sponsor: Eastern Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Million-Patient study aims to unravel cancer fatigue mystery
Knowledge-focused Recruiting nowThis study will follow 1 million Chinese adults with cancer to measure how common and severe cancer-related fatigue is. Researchers will look at what factors influence fatigue and how it affects treatment and survival. The goal is to better understand this common but often overlo…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Radiation's immune secrets: new trial probes rectal cancer response
Knowledge-focused Recruiting nowThis study is looking at how short-course radiation therapy (5 days of treatment) affects the immune system in people with rectal cancer. Researchers will collect blood, stool, and tumor tissue samples before, during, and after radiation to study these changes. The goal is to bet…
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
770 cancer patients join study to unlock immunotherapy secrets
Knowledge-focused Recruiting nowThis study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can your smartphone help fight cancer? new study aims to find out
Knowledge-focused Recruiting nowThis study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Gut bacteria may hold key to better cancer therapy
Knowledge-focused Recruiting nowThis study investigates whether the unique bacteria found inside digestive system tumors can help predict how well a patient will respond to neoadjuvant therapy (chemotherapy before surgery). Researchers will analyze tumor samples from 90 adults with pancreatic, gastric, colorect…
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
NIH launches massive GI data bank to fuel future discoveries
Knowledge-focused Recruiting nowThis study aims to collect medical data and biological samples (blood, urine, stool, and tissue) from up to 4,000 adults with known or suspected gastrointestinal diseases. Participants receive standard medical care at the NIH, and any extra samples or leftover tissue from procedu…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to unravel cancer blood clot mysteries
Knowledge-focused Recruiting nowThis study is collecting blood and urine samples from 150 cancer patients who have had blood clots. The goal is to learn more about why clots happen in cancer and how to prevent them. Participants will be followed over time to track clot recurrence and bleeding risks.
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
5,000 cancer patients enrolled to uncover proton Therapy's hidden risks
Knowledge-focused Recruiting nowThis study is collecting information on side effects from proton therapy in 5,000 adults with many types of cancer. Researchers will track both short-term and long-term side effects and link them to the details of each patient's treatment plan. The goal is to better predict who m…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Gut bacteria could hold key to rectal cancer prognosis
Knowledge-focused Recruiting nowThis study looks at whether the types of bacteria in the gut and surrounding tissues can help predict how rectal cancer will progress. Researchers will collect stool, tissue, and fat samples from 100 people with rectal cancer and compare them to healthy controls. The goal is to f…
Sponsor: University Hospital of Girona Dr. Josep Trueta • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Scientists probe immune resistance in tumors to outsmart cancer
Knowledge-focused Recruiting nowThis study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
500 cancer patients join quest to unlock precision medicine secrets
Knowledge-focused Recruiting nowThis study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New program aims to bridge cancer care gaps for native americans
Knowledge-focused Recruiting nowThis study is testing a program to help Native American cancer patients get better coordinated care. It brings together a cancer center and tribal health systems to improve communication and support. About 187 adults newly diagnosed with cancer will take part. The goal is to see …
Phase: NA • Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
NCI opens screening study for experimental cell therapies in multiple cancers
Knowledge-focused Recruiting nowThis study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Blood biopsy study aims to improve cancer detection and monitoring
Knowledge-focused Recruiting nowThis study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Mayo clinic launches study to grow tumors in the lab
Knowledge-focused Recruiting nowThis study collects tumor tissue, blood, and cheek swabs from 50 adults with cancer to create personalized 3D models in the lab. Researchers will analyze the genetics and drug responses of these models to find new treatment targets. The goal is to improve understanding of aggress…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New stitch could cut leak risk after colon surgery
Knowledge-focused Recruiting nowThis study looks at whether a specific dissolvable stitch (Monoplus) can lower the chance of a leak where the bowel is reconnected after colon cancer surgery. About 249 people having either keyhole or open surgery will take part. The main goal is to see if the leak rate within 30…
Sponsor: Aesculap AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Gut bacteria may hold key to safer cancer immunotherapy
Knowledge-focused Recruiting nowThis study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Can simple strategies boost genetic testing for cancer patients?
Knowledge-focused Recruiting nowThis study looks at ways to increase genetic testing for people with breast, pancreatic, or colorectal cancer. Researchers will try different methods—like training doctors, giving feedback, and improving electronic health records—to see what helps oncology teams order more tests.…
Phase: NA • Sponsor: Josh Peterson • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Blood samples may reveal how to boost Cancer-Fighting immune cells
Knowledge-focused Recruiting nowThis study collects blood or apheresis samples from 24 people with solid tumors and healthy volunteers. Researchers will analyze immune cells to see how they respond to a neoantigen vaccine, which is designed to help the immune system recognize cancer. The goal is to learn how to…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Massive global study aims to uncover why young cancer patients in poorer nations fare worse
Knowledge-focused Recruiting nowThis study will follow 6,000 children, adolescents, and young adults with cancer in low- and middle-income countries. Researchers will collect data from medical records and questionnaires to understand why treatment failure and severe side effects are more common in these setting…
Sponsor: Resonance, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC